Huaan Hang Seng Biotech ETF

159102

Shanghai Henlius Biotech Inc. has received approval from the National Medical Products Administration for its IND application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, aimed at treating advanced colorectal cancer. This marks a significant step as no SIRPα-Fc fusion protein targeting CD47 has been approved globally. However, the company cautions that successful development and commercialization of HLX701 is not guaranteed, advising shareholders and potential investors to exercise caution.

Reuters

Guotai CSI Bio-medicine ETF

HENLIUS

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Research Sector 100 ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application

Based in Santa Barbara, California, Artera.io has been acknowledged as the 162nd fastest-growing company in America. The company specializes in enhancing patient communications through the integration of human and AI agent intelligence. This recognition comes from Deloitte, as Artera.io secures a spot on the esteemed Technology Fast 500 list for the fifth year in a row.

Unusual Whales

SPDR S&P Biotech

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

China Southern Hang Seng Biotech ETF(QDII)

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Artera ranked 162 in Deloitte's 2025 Technology Fast 500 list. Several executive appointments announced.

520880

Goldman Sachs raises its price target for Novo Nordisk to 436 Danish kroner (previously 352), and reiterates its buy recommendation - BN

marketscreener

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares Biotechnology ETF

Bosera Hang Seng Health Care ETF(QDII)

Novo Nordisk A/S (B Shares) ADRhedged

Goldman Sachs Raises Price Target for Novo Nordisk to 436 Danish Kroner (352), Reiterates Buy - BN

159316

Boehringer Ingelheim and Simcere Pharmaceutical Group Ltd. have announced a licensing and collaboration agreement to develop SIM0709, a bispecific antibody targeting inflammatory bowel disease (IBD). This partnership aims to address unmet medical needs in IBD treatment, with Boehringer obtaining global rights (excluding China) and Simcere eligible for up to €1.058 billion in milestone payments. SIM0709, developed using Simcere's proprietary platform, has shown superior efficacy in preclinical studies. This marks Simcere's second licensing deal in autoimmune diseases, highlighting its commitment to innovative therapies.

prnewswire

E Fund Hang Seng SCHK Innovative Drug ETF

SIMCERE PHARMA

Bosera Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI HK Equities Medical and Health Integration ETF

23:53 ET
			
			
			
				
					Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten

Shanghai Henlius Biotech Inc. has received approval from the National Medical Products Administration for a clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 and HANSIZHUANG for treating advanced solid tumours. This combination therapy is unique as no similar treatment has been approved globally. However, the company warns that successful development or commercialization of these therapies is not guaranteed.

Henlius Biotech Wins Approval for Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours

513700

01530

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

Tip Ranks

Penghua CSI HK Connect Health Care Composite ETF

3SBIO

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

In Atlanta and Toronto, Euna Solutions®, a prominent provider of specialized cloud solutions for the public sector, is marking the achievement of Bingham Healthcare in southeastern Idaho. By utilizing Euna Grants, a cloud platform, Bingham Healthcare, a nonprofit health system, has significantly enhanced its grant capabilities. The organization has escalated its active grant applications from five to over sixteen yearly. Consequently, they now consistently secure individual awards annually.

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

SPDR S&P Health Equip

Bingham Healthcare increases grant success with Euna Grants, securing $700,000/year, growing to 16+ applications/year.

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

Hoth Therapeutics

HYGIEIA GROUP

ChinaAMC CSI All Share Health Care Devices ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

SPDR S&P Health

GF CSI HK Innovative Drugs Industry ETF(QDII)

FOSUN PHARMA

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

On January 28, 2026, in Shanghai, WuXi Biologics (stock symbol:, a prominent international Contract Research, Development, and Manufacturing Organization (CRDMO), partnered with Sinorda Biomedicine to collaboratively work on SND006, a groundbreaking drug. This strategic alliance aims to combine resources for the development and production of SND006, marking a significant step in the pharmaceutical industry.

WuXi Biologics

WUXI BIO

WuXi Biologicsand Sinorda Biomedicine partner to develop SND006, a bispecific antibody.

Sigrid Therapeutics has entered an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand its SiPore® technology into consumer oral health. This partnership aims to commercialize SiPore® after clinical validation, with Sigrid receiving upfront payments, milestones, and royalties. SiPore® is a proprietary technology that targets plaque and biofilm formation in the oral cavity. The global oral health market is significant, with a growing focus on preventive health and science-backed solutions.

Hwabao WP CSI Medical Service ETF

02:00 ET
			
			
				Sigrid Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health

China NMPA Approves Visen Pharmaceuticals' Lonapegsomatropin for Pediatric Growth Failure

VISEN PHARMA-B

China NMPA Approves Visen Pharmaceuticals' Lonapegsomatropin for Pediatric Growth Failure

CARsgen Therapeutics Forecasts Narrower 2025 Losses

CARSGEN-B

CARsgen Therapeutics Forecasts Narrower 2025 Losses

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Wallstreetcn

China Universal 800 Health Care ETF

ZZPZH

CR Sanjiu

TRAD CHI MED

TAIJI GROUP

TASLY

DRTG

E Fund CSI HK Equities Medical and Health Integration ETF

BAIYUNSHAN PH

YILING PHARMACEUTICAL

Yunnan Baiyao

JUMPCAN

TONG REN TANG

TONGRENTANGCM

GYBYS

Guotai SSE STAR Brand Name Drug ETF

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

- On January 27, Premier Li Qiang signed a decree announcing the revised Implementation Regulations of the Drug Administration Law, effective May 15, 2026.  
- The updated regulations, marking the first comprehensive revision in over 20 years, enhance drug research, approval processes, and production management, while emphasizing innovation and public access to safe medications.  
- Key changes include support for pediatric and rare disease drug exclusivity periods, stringent online sales regulations, and the introduction of a segmented production system to boost production efficiency.

BeOne Medicines

CSPC PHARMA

WuXi AppTec

JD HEALTH

CSPC Innovation

Pharmaron

Beigene

China Universal CNI HK Connect Innovative Drugs Industry ETF

WUXI APPTEC

Tigermed

Hwabao WP CSI Pharmaceuticals ETF

SINO BIOPHARM

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

Nanjing Leads Biolabs Co., Ltd. has received Orphan Drug Designation from the European Commission for its bispecific antibody LBL-024 (Opamtistomig) aimed at treating extrapulmonary neuroendocrine carcinoma (EP-NEC). This designation offers regulatory and commercial benefits, including market exclusivity for 10 years upon approval. LBL-024 is the first therapy targeting 4-1BB to reach the registrational stage for EP-NEC and has shown promising results in trials. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$80.27, and the company focuses on innovative oncology therapies.

LEADS BIOLABS-B

Nanjing Leads Biolabs Wins EU Orphan Drug Status for LBL-024 in Rare Neuroendocrine Cancer

Huaan Hang Seng Biotech ETF(159102.SZ)

Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application

Artera ranked 162 in Deloitte's 2025 Technology Fast 500 list. Several executive appointments announced.

Goldman Sachs Raises Price Target for Novo Nordisk to 436 Danish Kroner (352), Reiterates Buy - BN

23:53 ET Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten

Henlius Biotech Wins Approval for Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours